Tourmaline Bio (NASDAQ:TRML) Rating Reiterated by Leerink Partnrs
Leerink Partnrs reaffirmed their outperform rating on shares of Tourmaline Bio (NASDAQ:TRML – Free Report) in a report issued on Thursday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.00) EPS. TRML has been the subject of a number of other reports. Piper Sandler started coverage on Tourmaline Bio […]
More Stories
Fauci Refuses to Appear Before 2nd Senate Panel After Contempt Vote
By Tom Ozimek Dr. Anthony Fauci has declined a request to appear voluntarily before a second Senate panel, days after...
HHS Report on Alleged Pediatric Gender-Treatment Fraud: 5 Key Takeaways
By Stacy Robinson A report released Aug. 13 by the Department of Health and Human Services (HHS) has shined a...
North Korea Threatens Stronger Deterrence Ahead of US–South Korea Military Drills
By Victoria Friedman Pyongyang has denounced the upcoming annual joint U.S.–South Korean military drills on the peninsula, calling them provocative...
Trump Says He’ll Declare the Hormuz Strait a US Territory ‘Pretty Soon’
By Emel Akan President Donald Trump announced on Friday his intention to declare the Strait of Hormuz a U.S. territory,...
Hurricane Watch Issued for Hawaii’s Big Island as Tropical Storm Lala Forms
By Savannah Hulsey Pointer A hurricane watch has been issued for the Big Island of Hawaii as Tropical Storm Lala...
Earnings Are Up Over 50% So Far
By Louis Navellier Through last Friday, 88% of the S&P 500 companies have announced second-quarter results. According to FactSet Earnings...